ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

French health officials received dozens of reports of syringe pricks at a public festival, sparking fear about HIV and ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The Ghana HIV and AIDS Network (GHANET) is taking a proactive and strategic approach to combat the nation's HIV epidemic, focusing on a demographic often overlooked in health-seeking behaviours.

In recent months, reports of rising HIV infections in Malaysia have once again made national headlines. The data paints a ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...